109 related articles for article (PubMed ID: 12455450)
1. Antithyroid drug-induced immunomodulation in Graves' disease patients.
Lechpammer M; Lukac J; Lechpammer S; Kusić Z
Acta Med Croatica; 2002; 56(1):21-6. PubMed ID: 12455450
[TBL] [Abstract][Full Text] [Related]
2. Serum levels of the interferon-gamma-inducible alpha chemokine CXCL10 in patients with active Graves' disease, and modulation by methimazole therapy and thyroidectomy.
Antonelli A; Fallahi P; Rotondi M; Ferrari SM; Serio M; Miccoli P
Br J Surg; 2006 Oct; 93(10):1226-31. PubMed ID: 16838393
[TBL] [Abstract][Full Text] [Related]
3. Immunomodulation by methimazole therapy in Graves' disease: rapid changes in activation stage of circulating regulatory T cell subsets, B cells and NK cells.
Karlsson FA; Tötterman TH
Clin Exp Immunol; 1988 Nov; 74(2):258-63. PubMed ID: 2906281
[TBL] [Abstract][Full Text] [Related]
4. Methimazole treatment in Graves' disease: behaviour of CD5+B lymphocytes and regulatory T cell subsets.
Paggi A; Amoroso A; Ferri GM; Mariotti A; Pellegrino C; Afeltra A
Eur Rev Med Pharmacol Sci; 1998; 2(1):11-9. PubMed ID: 9825565
[TBL] [Abstract][Full Text] [Related]
5. Comparison of single daily dose of methimazole and propylthiouracil in the treatment of Graves' hyperthyroidism.
He CT; Hsieh AT; Pei D; Hung YJ; Wu LY; Yang TC; Lian WC; Huang WS; Kuo SW
Clin Endocrinol (Oxf); 2004 Jun; 60(6):676-81. PubMed ID: 15163329
[TBL] [Abstract][Full Text] [Related]
6. The distribution of the major peripheral blood T, B and NK cell subsets does not predict the clinical outcome of Graves' disease patients after methimazole therapy.
Corrales JJ; López A; Ciudad J; Orfao A
J Biol Regul Homeost Agents; 2000; 14(3):193-9. PubMed ID: 11037052
[TBL] [Abstract][Full Text] [Related]
7. Spiking expression of mu-crystallin mRNA during treatment with methimazole in patients with graves' hyperthyroidism.
Suzuki S; Takei M; Nishio S; Inaba H; Sato A; Yamazaki M; Shinomiya K; Hashizume K
Horm Metab Res; 2009 Jul; 41(7):548-53. PubMed ID: 19280551
[TBL] [Abstract][Full Text] [Related]
8. [Effect of thyroxine upon prevention of recurrence of Graves' disease treated with antithyroid drugs].
Wu G; Jie Y; Situ Y
Zhonghua Yi Xue Za Zhi; 2001 Mar; 81(5):274-5. PubMed ID: 11798886
[TBL] [Abstract][Full Text] [Related]
9. The effect of combination therapy with propylthiouracil and cholestyramine in the treatment of Graves' hyperthyroidism.
Tsai WC; Pei D; Wang TF; Wu DA; Li JC; Wei CL; Lee CH; Chen SP; Kuo SW
Clin Endocrinol (Oxf); 2005 May; 62(5):521-4. PubMed ID: 15853819
[TBL] [Abstract][Full Text] [Related]
10. Correction of insulin resistance in methimazole-treated patients with Graves disease.
Tene C; Zárate A; Basurto L; Islas S; Revilla C; Ochoa R; Galván R; Santos P
Rev Invest Clin; 2001; 53(6):531-5. PubMed ID: 11921526
[TBL] [Abstract][Full Text] [Related]
11. Influence of thyroxine on serum soluble interleukin-2 receptor alpha levels in thyroid disorders.
Zwirska-Korczala K; Berdowska A; Jochem J; Sitkiewicz A; Birkner E; Polaniak R; Jedrzejowska-Szypułka H; Korzonek-Szlacheta I
J Clin Pharm Ther; 2004 Apr; 29(2):151-6. PubMed ID: 15068404
[TBL] [Abstract][Full Text] [Related]
12. [Effects of methimazole on the evolution of the allergic rhinitis of patients with Graves' disease].
Valencia Zavala MP; Cortinas López L; Sánchez Olivas JA; Sánchez Olivas MA; Montes Montes J; Duarte Díaz RJ; León Oviedo C
Rev Alerg Mex; 2007; 54(3):71-6. PubMed ID: 17849791
[TBL] [Abstract][Full Text] [Related]
13. [Antibodies against TSH receptors (TRAb) as indicators in prognosing the effectiveness of Tiamazol therapy for Grave's Disease].
Bojarska-Szmygin A; Ciechanek R
Wiad Lek; 2003; 56(7-8):303-7. PubMed ID: 14969154
[TBL] [Abstract][Full Text] [Related]
14. [Assessment of early immunosuppressive therapy in the prevention of complications of Graves' disease].
Huszno B; Trofimiuk M; Gołkowski F; Plinta T; Szybiński Z
Przegl Lek; 2004; 61(8):868-71. PubMed ID: 15789920
[TBL] [Abstract][Full Text] [Related]
15. New therapeutic approaches in thyroidal autoimmune diseases.
Benker G; Esser J; Kahály G; Reinwein D
Klin Wochenschr; 1990; 68 Suppl 21():44-54. PubMed ID: 1695960
[TBL] [Abstract][Full Text] [Related]
16. Methimazole therapy in Graves' disease influences the abnormal expression of CD69 (early activation antigen) on T cells.
Corrales JJ; López A; Ciudad J; Mories MT; Miralles JM; Orfao A
J Endocrinol; 1997 Dec; 155(3):491-500. PubMed ID: 9487994
[TBL] [Abstract][Full Text] [Related]
17. Increase of interferon-gamma-inducible CXC chemokine CXCL10 serum levels in patients with active Graves' disease, and modulation by methimazole therapy.
Antonelli A; Rotondi M; Fallahi P; Romagnani P; Ferrari SM; Barani L; Ferrannini E; Serio M
Clin Endocrinol (Oxf); 2006 Feb; 64(2):189-95. PubMed ID: 16430719
[TBL] [Abstract][Full Text] [Related]
18. Supplementation with antioxidants in the treatment of Graves' disease; the effect on glutathione peroxidase activity and concentration of selenium.
Vrca VB; Skreb F; Cepelak I; Romic Z; Mayer L
Clin Chim Acta; 2004 Mar; 341(1-2):55-63. PubMed ID: 14967159
[TBL] [Abstract][Full Text] [Related]
19. [The effect of one-month antithyroid therapy on peripheral metabolism of reactive oxygen species in Graves' disease with infiltrative ophthalmopathy].
Bednarek J; Wysocki H; Sowiński J
Przegl Lek; 2004; 61(8):841-4. PubMed ID: 15789912
[TBL] [Abstract][Full Text] [Related]
20. Serial analysis of the effects of methimazole or radical therapy on circulating CD16/56 subpopulations in Graves' disease.
Rojano J; Sasián S; Gavilán I; Aguilar M; Escobar L; Girón JA
Eur J Endocrinol; 1998 Sep; 139(3):314-6. PubMed ID: 9758442
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
